Non-metastatic breast cancer.
Conditions
Interventions
Intervention 1: Intervention group: Urtica syrup containing nettle extract (standardized product based on at least 0.04 mg/ml chlorogenic acid, Zardband Company, Tehran, Iran) will be taken twice dail
Sponsors
Hamedan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Breast cancer according to pathology report Age over 18 years Informed consent Candidate for adjuvant chemotherapy and radiotherapy
Exclusion criteria
Exclusion criteria: Die during treatment Having depression or taking antidepressants during the follow-up period The occurrence of metastasis Breast cancer with estrogen or progesterone hormone receptor-positive cells that are candidates for hormone therapy Methylphenidate use Taking warfarin or other anticoagulant medications Systolic blood pressure less than 100 mmHg Long-term use of painkillers, alcohol, or illegal drugs Allergy to Urtica based on history taking Patients with any systemic disease Have received neoadjuvant treatment Pregnancy or breastfeeding Hemoglobin less than 12
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fatigue. Timepoint: 4 weeks after treatment. Method of measurement: Based on the brief fatigue questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactZahra Kesht pour amlashi
Hamedan University of Medical Sciences
Outcome results
None listed